GlassScriptPhysician profile
Jared Charles Richardson
NPI 1811259302
$4,002.30
in general payments reported to CMS, 2019-2025
37 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $978 · 2023: $1,012 · 2024: $550 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $626.18 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $375.11 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $359.19 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.79 | 2021-2024 | |
| Amgen INC. | $233.85 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $229.47 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $219.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $211.73 | 2022-2025 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $207.72 | 2022-2025 | Rexulti |
| Abbott Laboratories | $177.82 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.16 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $94.45 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $92.17 | 2021-2023 | Trintellix |
| Corcept Therapeutics | $89.39 | 2025 | Korlym |
| Astellas Pharma US INC | $81.47 | 2025 | Veozah |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.